Robbins LLP Is Investigating the Officers and Directors of Pulse Biosciences, Inc.

On July 31, 2018, Pulse Biosciences disclosed that it had received subpoenas from the U.S. Securities and Exchange Commission requesting documents and information related to an investigation into trading in the company's stock in advance of its September 2017 financing announcement. Pulse further revealed that on July 30, 2018, the company received a letter from Nasdaq stating that Pulse is not in compliance with Nasdaq's audit committee requirements and has until July 27, 2019 to regain compliance.

Pulse Biosciences Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can send us a message via the Shareholder Information form below.